Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Endo International PLC (NASDAQ:ENDP)

8.00
Delayed Data
As of Dec 15
 0.00 / 0.00%
Today’s Change
5.77
Today|||52-Week Range
17.99
-51.43%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$1.7B

Company Description

Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The company operates through the following segments: U.S. Branded Pharmaceuticals, U.S. Generic pharmaceuticals and International Pharmaceuticals. The U.S. Branded Pharmaceuticals offers products that focus on the treatment and management of conditions in urology, urologic oncology, endocrinology, and orthopedics. The U.S. Generic pharmaceuticals segment consist of a differentiated product portfolio including high-barrier-to-entry products, first-to-file or first-to-market opportunities that are difficult to formulate, difficult to manufacture or face complex legal and regulatory challenges. The International Pharmaceuticals segment includes a variety of pharmaceutical products for the Canadian, Latin American, South African, and world markets. Endo International was founded on October 31, 2013 and is headquartered Dublin, Ireland.

Contact Information

Endo International Plc
Minerva House
Dublin Dublin 4
P:(531) 268-2000
Investor Relations:

Employees

Shareholders

Other institutional51.52%
Mutual fund holders35.30%
Individual stakeholders0.81%

Top Executives

Paul V. CampanelliPresident, Chief Executive Officer & Director
Terrance J. CoughlinChief Operating Officer & Executive Vice President
Blaise ColemanChief Financial Officer & Executive Vice President
Robert J. CobuzziSVP-Operations, Research & Development Strategy
Jennifer E. DubasVice President & Chief Compliance Officer